Plant compound more powerful than AZT against HIV

June 15, 2017 by Sharon Parmet, University of Illinois at Chicago
Willow-leaved Justicia. Credit: University of Illinois at Chicago

A plant found throughout Southeast Asia traditionally used to treat arthritis and rheumatism contains a potent anti-HIV compound more powerful than the drug AZT, according to a new paper published in the Journal of Natural Compounds.

The chemical, patentiflorin A, is derived from the willow-leaved Justicia, and was identified in a screening of more than 4,500 plant extracts for their effect against the HIV virus.

The discovery is one of the results of a multi-year research partnership made up of scientists from the University of Illinois at Chicago, Hong Kong Baptist University, and the Vietnam Academy of Science and Technology working together as an International Cooperative Biodiversity Group. These groups, funded by the National Institutes of Health, National Science Foundation and the U.S. Department of Agriculture, look for natural products that may have applications in health and medicine, and also work to support sustainable use of these resources in low-income countries.

Lijun Rong, professor of microbiology and immunology in the UIC College of Medicine; Harry Fong, associate director of the World Health Organization Program for Traditional Medicine; and Doel Soejarto, professor emeritus of medicinal chemistry and pharmacognosy in the UIC College of Pharmacy, led the UIC team. Rong is an expert at identifying antiviral agents, Soejarto is a renowned plant scientist, and Fong is a well-known pharmacologist.

The willow-leaved Justicia extract had been taken from the leaves, stems and roots of plants that had been collected in Cuc Phuong National Park in Hanoi, Vietnam more than 10 years ago by Soejarto. The UIC/Hong Kong/Vietnam ICBG analyzed the extract along with thousands of others as part of their efforts to identify new drugs against HIV, tuberculosis, malaria and cancer.

Rong and his colleagues zeroed in on patentiflorin A because of its ability to inhibit an enzyme needed for HIV to incorporate its genetic code into a cell's DNA. AZT, the first anti-HIV drug developed and marketed in 1987, and which remains the cornerstone of HIV drug cocktails today, inhibits this enzyme, called reverse transcriptase. In studies of human cells infected with the HIV virus, patentiflorin A had a much more significant inhibition effect on the enzyme.

"Patentiflorin A was able to inhibit the action of reverse transcriptase much more effectively than AZT, and was able to do this both in the earliest stages of HIV infection when the virus enters macrophage cells, and alter infection when it is present in T cells of the immune system," said Rong.

It also was effective against known drug-resistant strains of the HIV virus, making it a very promising candidate for further development into a new HIV drug.

"Patentiflorin A represents a novel anti-HIV agent that can be added to the current anti-HIV drug cocktail regimens to increase suppression of the virus and prevention of AIDS," Rong said.

The researchers were also able to synthesize patentiflorin A. "If we can make the in the lab, we don't need to establish farms to grow and harvest the plant, which requires significant financial investment, not to mention it has an environmental impact," Rong said.

Explore further: Familiar drugs may block Ebola virus infection

More information: Hong-Jie Zhang et al. Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant, Journal of Natural Products (2017). DOI: 10.1021/acs.jnatprod.7b00004

Related Stories

Familiar drugs may block Ebola virus infection

August 7, 2015
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus's entry into cells and halt the disease in its tracks, according to researchers at the University of ...

New Zika virus inhibitor identified

May 16, 2017
New research led by Alexey Terskikh, Ph.D., associate professor at Sanford Burnham Prebys Medical Discovery Institute (SBP), and Alex Strongin, Ph.D., professor at SBP, could be a first step toward a drug to treat Zika infections. ...

Plant-derived products may help fight HBV

January 17, 2017
Researchers have found that certain plant-derived products may help prevent and treat hepatitis B virus (HBV) infection. Proanthocyanidin (PAC) and its analogs, oolonghomobisflavanes, act by inhibiting viral entry into host ...

Cell culture experiments reveal potent antiviral activity of Cistus incanus extracts against HIV and Ebola

February 2, 2016
Scientists at the Helmholtz Zentrum München discover that extracts of the medicinal plant Cistus incanus (Ci) prevent human immunodeficiency viruses from infecting cells. Active antiviral ingredients in the extracts inhibit ...

Researchers find that certain anti-influenza compounds also inhibit Zika virus infection

January 16, 2017
Researchers from the University of Helsinki have shown that three anti-influenza compounds effectively inhibit Zika virus infection in human cells. The results provide the foundation for development of the broad-spectrum ...

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.